Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Finished Goods (2017 - 2025)

Ultragenyx Pharmaceutical has reported Finished Goods over the past 9 years, most recently at $25.0 million for Q4 2025.

  • Quarterly Finished Goods rose 8.7% to $25.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.0 million through Dec 2025, up 8.7% year-over-year, with the annual reading at $25.0 million for FY2025, 8.7% up from the prior year.
  • Finished Goods was $25.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $23.0 million in the prior quarter.
  • Over five years, Finished Goods peaked at $26.7 million in Q2 2025 and troughed at $4.9 million in Q2 2022.
  • The 5-year median for Finished Goods is $12.1 million (2023), against an average of $13.5 million.
  • Year-over-year, Finished Goods dropped 13.08% in 2022 and then surged 107.99% in 2023.
  • A 5-year view of Finished Goods shows it stood at $5.7 million in 2021, then soared by 62.04% to $9.3 million in 2022, then surged by 62.82% to $15.1 million in 2023, then surged by 52.22% to $23.0 million in 2024, then rose by 8.7% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Finished Goods are $25.0 million (Q4 2025), $23.0 million (Q3 2025), and $26.7 million (Q2 2025).